PT2829545T - Novos derivados fosfatados, processo para a sua preparação e composições farmacêuticas que os contenham - Google Patents

Novos derivados fosfatados, processo para a sua preparação e composições farmacêuticas que os contenham

Info

Publication number
PT2829545T
PT2829545T PT141780304T PT14178030T PT2829545T PT 2829545 T PT2829545 T PT 2829545T PT 141780304 T PT141780304 T PT 141780304T PT 14178030 T PT14178030 T PT 14178030T PT 2829545 T PT2829545 T PT 2829545T
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
compositions containing
preparing same
phosphate derivatives
new phosphate
Prior art date
Application number
PT141780304T
Other languages
English (en)
Portuguese (pt)
Inventor
De Nanteuil Guillaume
Geneste Olivier
Le Tiran Arnaud
Le Diguarher Thierry
Starck Jérôme-Benoît
Henlin Jean-Michel
Guillouzic Anne-Françoise
Edward Paul Davidson James
Brooke Murray James
Chen I-Jen
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2829545(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of PT2829545T publication Critical patent/PT2829545T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT141780304T 2013-07-23 2014-07-22 Novos derivados fosfatados, processo para a sua preparação e composições farmacêuticas que os contenham PT2829545T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357259A FR3008979B1 (fr) 2013-07-23 2013-07-23 Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PT2829545T true PT2829545T (pt) 2016-07-13

Family

ID=50288170

Family Applications (1)

Application Number Title Priority Date Filing Date
PT141780304T PT2829545T (pt) 2013-07-23 2014-07-22 Novos derivados fosfatados, processo para a sua preparação e composições farmacêuticas que os contenham

Country Status (48)

Country Link
US (3) US9115159B2 (ru)
EP (1) EP2829545B1 (ru)
JP (1) JP5894638B2 (ru)
KR (2) KR101713103B1 (ru)
CN (1) CN104341451B (ru)
AP (1) AP2014007773A0 (ru)
AR (1) AR097008A1 (ru)
AU (1) AU2014203808B2 (ru)
BR (1) BR102014017997B1 (ru)
CA (1) CA2856886C (ru)
CL (1) CL2014001865A1 (ru)
CR (1) CR20140336A (ru)
CU (1) CU24316B1 (ru)
CY (1) CY1117834T1 (ru)
DK (1) DK2829545T3 (ru)
DO (1) DOP2014000163A (ru)
EA (1) EA027444B1 (ru)
EC (1) ECSP14008757A (ru)
ES (1) ES2593417T3 (ru)
FR (1) FR3008979B1 (ru)
GE (1) GEP201706704B (ru)
HK (2) HK1201536A1 (ru)
HR (1) HRP20161202T8 (ru)
HU (1) HUE029616T2 (ru)
IL (1) IL233580B (ru)
JO (1) JO3160B1 (ru)
MA (1) MA37213B1 (ru)
MD (1) MD4551C1 (ru)
ME (1) ME02641B (ru)
MX (1) MX351467B (ru)
MY (1) MY173258A (ru)
NI (1) NI201400080A (ru)
PE (1) PE20150218A1 (ru)
PH (1) PH12014000194B1 (ru)
PL (1) PL2829545T3 (ru)
PT (1) PT2829545T (ru)
RS (1) RS55098B1 (ru)
RU (1) RU2617682C2 (ru)
SA (1) SA114350669B1 (ru)
SG (1) SG10201403939WA (ru)
SI (1) SI2829545T1 (ru)
SV (1) SV2014004771A (ru)
TN (1) TN2014000301A1 (ru)
TW (1) TWI527824B (ru)
UA (1) UA119738C2 (ru)
UY (1) UY35661A (ru)
WO (1) WO2015011399A1 (ru)
ZA (1) ZA201405418B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37316A (es) * 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
TWI759316B (zh) * 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
BR112019001024A2 (pt) * 2016-07-22 2019-05-14 Les Laboratoires Servier combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
AR112440A1 (es) * 2017-07-06 2019-10-30 Servier Lab Forma cristalina de un inhibidor de bcl-2, un proceso para su preparación y composiciones farmacéuticas que la contienen
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
CN110606860B (zh) * 2019-09-29 2021-12-10 上海勋和医药科技有限公司 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
JP2024508948A (ja) * 2021-03-12 2024-02-28 エイル セラピューティクス,インコーポレイテッド Bcl-2阻害剤としてのテトラヒドロインドリジン-1-カルボキサミドを有する化合物
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004004727A1 (en) * 2002-07-03 2004-01-15 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CN101356159A (zh) 2005-12-22 2009-01-28 惠氏公司 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
AU2008242983B2 (en) * 2007-04-16 2013-07-11 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
PT2149560E (pt) * 2007-05-22 2015-07-13 Astellas Pharma Inc Composto de tetra-hidroisoquinolina substituído na posição 1
AU2009215191A1 (en) * 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
BRPI0918360A8 (pt) * 2008-12-19 2017-12-05 Genentech Inc Composto, composição farmacêutica e usos de um composto
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en) 2011-05-23 2012-11-29 Senko Advanced Components, Inc. True one piece housing fiber optic adapter
BR112014015308A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
MX2014007725A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140107573A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
BR112014015322A8 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
CN103177906A (zh) 2011-12-26 2013-06-26 西门子公司 用于中压开关设备的断路器
ITPR20110103A1 (it) 2011-12-27 2013-06-28 G E A F S R L Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en) 2011-12-29 2015-08-25 Inventio Ag Emergency operation of elevators based on an indicated emergency condition
IN2012DE00210A (ru) 2012-01-24 2015-06-19 Danfoss As
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HUE029616T2 (en) 2017-03-28
NZ627178A (en) 2016-01-29
IL233580B (en) 2020-03-31
MX351467B (es) 2017-10-17
AU2014203808B2 (en) 2018-09-20
SV2014004771A (es) 2015-01-28
ES2593417T3 (es) 2016-12-09
EP2829545A1 (fr) 2015-01-28
RU2617682C2 (ru) 2017-04-26
TW201504254A (zh) 2015-02-01
BR102014017997B1 (pt) 2020-05-19
EA201400754A2 (ru) 2014-12-30
HRP20161202T1 (hr) 2016-11-04
WO2015011399A1 (fr) 2015-01-29
PL2829545T3 (pl) 2016-12-30
KR20170001694A (ko) 2017-01-04
US20150313923A1 (en) 2015-11-05
RU2014130129A (ru) 2016-02-10
SA114350669B1 (ar) 2016-04-11
DOP2014000163A (es) 2015-01-15
TN2014000301A1 (fr) 2015-12-21
FR3008979A1 (fr) 2015-01-30
EA027444B1 (ru) 2017-07-31
US9597341B2 (en) 2017-03-21
MX2014008866A (es) 2015-07-21
JP2015028017A (ja) 2015-02-12
MD4551C1 (ru) 2018-09-30
PH12014000194A1 (en) 2015-06-29
CU24316B1 (es) 2018-02-08
AR097008A1 (es) 2016-02-10
US9115159B2 (en) 2015-08-25
DK2829545T3 (en) 2016-09-19
EA201400754A3 (ru) 2015-03-31
TWI527824B (zh) 2016-04-01
HK1201536A1 (zh) 2015-09-04
MY173258A (en) 2020-01-09
ME02641B (me) 2017-06-20
IL233580A0 (en) 2014-11-02
RS55098B1 (sr) 2016-12-30
CY1117834T1 (el) 2017-05-17
SI2829545T1 (sl) 2016-10-28
US20150031648A1 (en) 2015-01-29
MD20140073A2 (ru) 2015-01-31
UA119738C2 (uk) 2019-08-12
KR101713103B1 (ko) 2017-03-07
AP2014007773A0 (en) 2014-07-31
GEP201706704B (en) 2017-07-25
PH12014000194B1 (en) 2015-06-29
CU20140095A7 (es) 2016-02-29
CN104341451B (zh) 2018-04-03
MD4551B1 (ru) 2018-02-28
MA37213B1 (fr) 2017-03-31
KR20150011785A (ko) 2015-02-02
MA37213A1 (fr) 2016-06-30
ECSP14008757A (es) 2016-01-29
CL2014001865A1 (es) 2015-06-26
PE20150218A1 (es) 2015-02-14
CR20140336A (es) 2015-10-07
HRP20161202T8 (hr) 2016-12-30
UY35661A (es) 2015-02-27
JP5894638B2 (ja) 2016-03-30
CN104341451A (zh) 2015-02-11
US20170143746A1 (en) 2017-05-25
JO3160B1 (ar) 2017-09-20
NI201400080A (es) 2014-10-24
HK1204623A1 (en) 2015-11-27
FR3008979B1 (fr) 2015-07-24
CA2856886A1 (fr) 2015-01-23
CA2856886C (fr) 2016-08-02
SG10201403939WA (en) 2015-02-27
ZA201405418B (en) 2020-02-26
BR102014017997A2 (pt) 2015-11-17
AU2014203808A1 (en) 2015-02-12
EP2829545B1 (fr) 2016-06-22

Similar Documents

Publication Publication Date Title
HRP20161202T8 (hr) Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
ME02635B (me) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
HK1215567A1 (zh) 五元併六元雜環化合物、其製備方法、藥物組合物和應用
PL3061747T3 (pl) Pochodne ketonów pirydynowych, sposób ich wytwarzania i ich zastosowanie farmaceutyczne
PL2807159T3 (pl) Nowe pochodne indolizyny, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające do leczenia raka
IL243226B (en) History of pyrazole, their preparation and pharmaceutical preparations containing them
LT3064498T (lt) Pirazolpirimidono arba piroltriazono dariniai, jų paruošimo būdas ir jų farmacinis panaudojimas
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
IL243227B (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
EP2941418A4 (en) N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
IL243223B (en) History of imidazole, their preparation and pharmaceutical preparations containing them
HK1206329A1 (en) Phenol derivative, method of preparing same, and pharmaceutical application of same
EP3078659A4 (en) 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL239873B (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
IL244102B (en) The history of cyclopentylamine, their preparation and pharmaceutical preparations containing them
AP2015008475A0 (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same